Revvity Inc. has launched its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with artificial intelligence (AI) capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all designed to help accelerate scientific discovery.

“Our Living Image Synergy AI software marks a significant leap forward in preclinical imaging analysis,” Revvity Vice President of Platforms Kevin Quick said. “Tracking, monitoring, and visualizing biological processes and disease progression is central to understanding complex biology and evaluating potential therapeutics early in development. By unifying disparate analysis tools and integrating AI into existing workflows, Revvity’s new solution is directed towards enabling earlier insights and more consistent analysis across modalities, and greater reproducibility across studies—ultimately helping researchers move faster and with more confidence.”

The Living Image Synergy AI software centralizes analysis to eliminate the need for separate tools and enable seamless dataset correlation. Revvity developed this unified approach to help researchers uncover biological insights that might otherwise remain hidden when using isolated systems.

To further streamline workflows, the software features intuitive co-registration tools and automated processes that reduce manual tasks and analysis time. Advanced AI algorithms automate image segmentation and region-of-interest (ROI) quantification—traditionally labor-intensive and variable steps in imaging analysis. This helps support high-throughput analysis and allows researchers to more efficiently monitor disease progression and assess therapeutic efficacy with greater accuracy and statistical confidence, according to the company.

Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing the possibilities in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 160 countries.